Disease · HP_0030828
Wheezing
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Wheezing. Diseases, record HP_0030828. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0030828
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Wheezing
- Open Targets ID
- HP_0030828
- Highest stage of its drugs
- Phase 3, for 10 of its 13 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs13
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ALBUTEROL | CHEMBL714 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| MONTELUKAST | CHEMBL787 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| BUDESONIDE | CHEMBL1370 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| AZITHROMYCIN | CHEMBL529 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| DEXAMETHASONE | CHEMBL384467 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ALBUTEROL SULFATE | CHEMBL1441059 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| AMOXICILLIN | CHEMBL1082 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BECLOMETHASONE DIPROPIONATE | CHEMBL1200500 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CICLESONIDE | CHEMBL2040682 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ZINC SULFATE | CHEMBL1200929 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 13
See all 13 drugsTargets4
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 5 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| ADRB2 | Beta-2 adrenergic receptor | 2 | Beta-2 adrenergic receptor agonist | Phase 3 | https://conductscience.org/library/genes/154 | Drugs and targets |
| CHRM3 | Muscarinic acetylcholine receptor M3 | 1 | Muscarinic acetylcholine receptor M3 antagonist | Phase 2 | https://conductscience.org/library/genes/1131 | Drugs and targets |
| CYSLTR1 | Cysteinyl leukotriene receptor 1 | 1 | Cysteinyl leukotriene receptor 1 antagonist | Phase 3 | https://conductscience.org/library/genes/10800 | Drugs and targets |
Trials20
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00675584 | CARE Network Maintenance Versus Intermittent Inhaled Steroids in Wheezing Toddlers (MIST) | Phase 3 | 278 | 2012-06-01 | Asthma | BUDESONIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00115297 | Montelukast for Early Life Wheezing | Phase 2/3 | 62 | 2017-02-06 | Lung Diseases, Asthma | MONTELUKAST | Its record names the disease | ClinicalTrials.gov |
| NCT03421730 | A Study of the Pharmacokinetics, Safety and Tolerability of Single Doses of VR647 Inhalation Suspension Administered Using the VR647 Inhalation System in Children With Wheezing, Reactive Airway Disease or Mild Asthma | Phase 1 | 17 | 2019-10-21 | Wheezing, Reactive Airway Disease, Mild Asthma | BUDESONIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00407394 | Indiaclen Short Course Amoxycillin Therapy for Pneumonia With Wheeze | Phase 3 | 2,000 | Non-Severe Pneumonia With Wheeze | AMOXICILLIN | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT01142505 | Wheeze and Intermittent Treatment | Phase 3 | 1,358 | Wheezing | MONTELUKAST | Its record names the disease | ClinicalTrials.gov | |
| NCT00163449 | Efficacy and Safety of Ciclesonide in Preschool Children With Asthma (2 to 6 Years) (BY9010/M1-207) | Phase 3 | 1,000 | Asthma | CICLESONIDE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT04669288 | AZithromycin Therapy in Preschoolers With a Severe Wheezing Episode Diagnosed at the Emergency Department | Phase 3 | 840 | Asthma, Wheezing | AZITHROMYCIN | Its record names the disease | ClinicalTrials.gov | |
| NCT01008761 | Trial for the Treatment of Acute Asthma in Wheezy Pre-school Aged Children | Not applicable | 440 | Asthma | AZITHROMYCIN | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT00355043 | Efficacy of Zinc in the Treatment of Bronchiolitis and Prevention of Wheezing Respiratory Illness in Children Less Than Two Years Old | Phase 3 | 330 | Bronchiolitis | ZINC SULFATE | Its record names the disease | ClinicalTrials.gov | |
| NCT00497523 | Efficacy and Safety of Nebulised Beclomethasone Dipropionate Plus as Needed Salbutamol vs as Needed Salbutamol or as Needed Salbutamol/Beclomethasone Fixed Combination in Young Children With Asthma Symptoms | Phase 3 | 283 | Bronchial Asthma | ALBUTEROL, BECLOMETHASONE DIPROPIONATE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 20
See all 20 trialsComparisons in its trials6
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Daily Budesonide vs Intermittent Budesonide: Number of Participants With Treatment Failure | 17 of 139 | 9 of 139 | 278 | NCT00675584 | Trial comparisons |
| Daily Budesonide vs Intermittent Budesonide: Adverse Events Associated With Corticosteroid Use | 3 of 139 | 0 of 139 | 278 | NCT00675584 | Trial comparisons |
| Daily Budesonide vs Intermittent Budesonide: serious adverse events | 7 of 139 | 10 of 139 | 278 | NCT00675584 | Trial comparisons |
| Montelukast vs Placebo: Wheezing at Day 7 | 10 of 30 | 22 of 32 | 62 | NCT00115297 | Trial comparisons |
| Montelukast vs Placebo: The Number of Participants Requiring Rescue Beta Agonist Use | 15 of 30 | 26 of 32 | 62 | NCT00115297 | Trial comparisons |
| Montelukast vs Placebo: serious adverse events | 0 of 30 | 0 of 32 | 62 | NCT00115297 | Trial comparisons |
Papers from its trials19
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0030828
GET https://conductscience.org/api/diseases/v1/HP_0030828/drugs